Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 11:18 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 770 matching trials from the live ClinicalTrials.gov search.
Conditions
Sickle Cell Anemia
Interventions
Hydroxyurea
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
2 Years to 10 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Memphis, Tennessee
Completed No phase listed Observational Accepts healthy volunteers

Improving Scientific Rigor of Renal Clinical Endpoints for Sickle Cell Anemia

NCT04380610
Conditions
Sickle Cell Disease, Renal Disease, Glomerular Disease
Interventions
iohexol GFR
Diagnostic Test
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
5 Years to 50 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
4
States / cities
Birmingham, Alabama • Chicago, Illinois • Memphis, Tennessee
Conditions
Sickle Cell Disease, Sickle-Beta Zero Thalassemia
Interventions
SCD-101
Drug
Lead sponsor
Invenux, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
1
States / cities
Brooklyn, New York
Conditions
Sickle Cell Disease
Interventions
Not listed
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Sickle Cell Disease, Beta Thalassemia
Interventions
Busulfan, Fludarabine, Alemtuzumab, Allogeneic stem cell transplant
Drug · Procedure
Lead sponsor
Columbia University
Other
Eligibility
1 Month to 30 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2025
U.S. locations
1
States / cities
New York, New York
Recruiting No phase listed Observational

ATHNdataset Registry

NCT06820515
Conditions
Hemophilia, Thrombosis, Hemophilia A, Hemophilia B, Sickle Cell Disease, Glanzmann Thrombasthenia, Bleeding Disorder, Blood Disorder, Von Willebrand Diseases
Interventions
Not listed
Lead sponsor
American Thrombosis and Hemostasis Network
Network
Eligibility
Not listed
Enrollment
200,000 participants
Timeline
2024 – 2055
U.S. locations
1
States / cities
Hickory, North Carolina
Completed No phase listed Observational

Genes Influencing Iron Overload State

NCT01158794
Conditions
Sickle Cell Disease, Thalassemia, Marrow Aplasia
Interventions
Not listed
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Not listed
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2019
U.S. locations
1
States / cities
Memphis, Tennessee
Conditions
Leukemia, Lymphoma, Bone Marrow Failure, Immunodeficiencies, Histiocytosis, Sickle Cell Disease, Beta Thalassemia, Inborn Errors of Metabolism
Interventions
Full Intensity with TBI, Full Intensity, Reduced Intensity, Reduced Intensity (Fanconi)
Drug
Lead sponsor
New York Medical College
Other
Eligibility
Up to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Valhalla, New York
Conditions
Acute Leukemia, Severe Aplastic Anemia, Non-hodgkin Lymphoma, Hodgkin Lymphoma, Kostmann, Diamond Blackfan Anemia, Amegakaryocytic Thrombocytopenia, Sickle Cell Disease, Beta-Thalassemia
Interventions
alpha beta depletion
Drug
Lead sponsor
Mitchell Cairo
Other
Eligibility
1 Day to 30 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Valhalla, New York
Terminated Not applicable Interventional Results available

Alefacept and Allogeneic Hematopoietic Stem Cell Transplantation

NCT01319851
Conditions
Thalassemia, Sickle Cell Disease, Glanzmann Thrombasthenia, Wiskott-Aldrich Syndrome, Chronic-granulomatous Disease, Severe Congenital Neutropenia, Leukocyte Adhesion Deficiency, Schwachman-Diamond Syndrome, Diamond-Blackfan Anemia, Fanconi Anemia, Dyskeratosis-congenita, Chediak-Higashi Syndrome, Severe Aplastic Anemia
Interventions
Alefacept
Drug
Lead sponsor
Emory University
Other
Eligibility
Up to 21 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
Sickle Cell Disease
Interventions
Deferoxamine, Deferasirox, Deferiprone, Echocardiography, Electrocardiogram (ECG)
Drug · Device
Lead sponsor
Inova Health Care Services
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Fairfax, Virginia • Falls Church, Virginia
Completed No phase listed Observational Accepts healthy volunteers

Screening for Subjects to Participate in Studies of Blood Disorders

NCT00695123
Conditions
Bone Marrow Transplant, Sickle Cell Disease, G-CSF
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
Not listed
Enrollment
816 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Pneumococcal Infections
Interventions
V114, Prevnar 13™
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
5 Years to 17 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
6
States / cities
Wilmington, Delaware • Atlanta, Georgia • Detroit, Michigan + 3 more
Conditions
Sickle Cell Disease
Interventions
Losartan
Drug
Lead sponsor
Emory University
Other
Eligibility
9 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
2
States / cities
Atlanta, Georgia
Conditions
Sickle Cell Disease
Interventions
Alemtuzumab, Cyclophosphamide, Mycophenolate mofetil, Sirolimus, Fludarabine, Total body irradiation, Hematopoietic stem cell transplant
Drug · Radiation · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
19 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Sickle Cell Disease
Interventions
Music Therapy, Standard of Care
Other
Lead sponsor
Emory University
Other
Eligibility
8 Years to 18 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Atlanta, Georgia
Completed No phase listed Observational Results available

A Study to Learn About Sickle Cell Disease In Adult Patients

NCT05407805
Conditions
Sickle Cell Disease
Interventions
Electronic Diary
Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
4
States / cities
Hollywood, Florida • Upper Marlboro, Maryland • Waltham, Massachusetts + 1 more
Conditions
Sickle Cell Disease
Interventions
Defibrotide
Drug
Lead sponsor
New York Medical College
Other
Eligibility
6 Months to 21 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
4
States / cities
Los Angeles, California • Gainesville, Florida • Valhalla, New York + 1 more
Conditions
Sickle Cell Disease
Interventions
Mobile DOT
Behavioral
Lead sponsor
Emory University
Other
Eligibility
2 Years to 65 Years
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Atlanta, Georgia • Chicago, Illinois + 1 more
Conditions
Sickle Cell Disease
Interventions
Ticagrelor, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 30 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
3
States / cities
Miami, Florida • Bethesda, Maryland • Charleston, South Carolina
Conditions
Sickle Cell Disease, Hydroxyurea Failure, Hydroxyurea Intolerance, Hemoglobinopathies, Hematological Diseases
Interventions
CTX001
Biological
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
2 Years to 11 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
4
States / cities
Charlotte, North Carolina • Philadelphia, Pennsylvania • Memphis, Tennessee + 1 more
Conditions
Sickle Cell Crisis, Sickle Cell Disease
Interventions
Mindfulness meditation, breathing exercises (including incentive spirometry), and yoga therapy
Behavioral
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Dallas, Texas
Recruiting Not applicable Interventional

SickleFit Exercise and Nutrition Study

NCT07442851
Conditions
Sickle Cell Disease, Aging
Interventions
SickleFit Exercise plus Nutrition
Behavioral
Lead sponsor
Duke University
Other
Eligibility
35 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Sickle Cell Disease
Interventions
ketamine
Drug
Lead sponsor
Connecticut Children's Medical Center
Other
Eligibility
7 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
2
States / cities
Farmington, Connecticut • Hartford, Connecticut